Company News: AstraZeneca and Astra Tech

Share this article:

AstraZeneca has put its Astra Tech dental implant and medical device unit on the block for about $2 billion, various news outlets reported. The sale price reflects 3.4 times the Swedish division's earnings, according to a Reuters report. JP Morgan Chase has been hired to broker the sale. Astra Tech's dental implants, catheters, breathing aids and blood-management systems for surgery brought in about 3.9 billion Swedish crowns ($588 million) last year, and the unit employs around 2,200 staff. As part of its effort to jettison non-core businesses, AZ also seeks to sell a US chain of outpatient cancer centers called Aptium Oncology, which would likely fetch $500 million or less.

A survey of online promotion of drugs to professionals found that more than 150 brands used e-details and online events for the first time in 2010. Amgen's Prolia led the newbies with more than 7,600 online promotional activities during the first nine months of the year, said SDI, which produced the study. Merck's Dulera and AstraZeneca's Vimovo were right behind it with 6,100 and 4,100 activities, respectively. Overall, Merck's Singulair was tops in e-promotion, with 110,000-plus activities for the first nine months of 2010, followed by Pfizer's Pristiq, with 104,000 and Merck's Januvia with 89,000.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.